Compared with lincomycin, clindamycin phosphate has 4-8 times stronger antibacterial activity, better absorption, high bone tissue concentration, and strong antibacterial activity against both Gram-positive cocci and anaerobes. Clinically, it is mainly used for the treatment of tonsillitis, suppurative otitis media, sinusitis, acute bronchitis, acute exacerbation of chronic bronchitis, pneumonia, lung abscess, bronchiectasis complicated with infection, and skin and soft tissue infections such as furuncle, carbuncle, abscess, cellulitis, wound infection, burn infection, postoperative infection, etc. It is also used for acute urethritis, acute pyelonephritis, prostatitis and other urinary system infections, as well as osteomyelitis, septicemia, peritonitis, oral infections, etc.

Highly effective prodrug: Converts to clindamycin in vivo to exert antibacterial effects, with remarkable efficacy against Gram-positive bacteria and anaerobes.  

Good water solubility: Easily soluble in water, suitable for preparing injections, especially for intravenous administration.  

Strong stability: More stable than clindamycin hydrochloride, suitable for the development of multiple dosage forms.  

Rapid onset of action: Rapidly hydrolyzes into active components after injection, with a fast peak plasma concentration.  

Excellent tissue penetration: Well-distributed in tissues such as bone, joints, and lungs, suitable for the treatment of deep infections.  

Wide application: Used for the treatment of severe infections, postoperative prophylaxis, osteomyelitis, etc.